A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating Type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, March 29, 2023.
George Frey | Reuters
The Biden administration on Friday unveiled the next 15 prescription drugs that will be subject to price negotiations between manufacturers and Medicare, kicking off the second phase of a landmark process that aims to make costly medications more affordable for seniors.
Topping the list are Novo Nordisk‘s blockbuster diabetes injection Ozempic, weight loss shot Wegovy and diabetes pill Rybelsus, which are considered one product in the talks since they all share the same active ingredient: semaglutide. Those treatments fueled the rise of the red-hot obesity drug market and have been difficult for patients to access due to cost, insurance coverage and supply constraints.
The agreed-upon prices for the second wave of drugs are scheduled to go into effect in 2027. But it’s unclear whether President-elect Donald Trump could try to change or scale back some of the law’s provisions when he takes office next week.
Here are the 15 drugs subject to the initial talks this year:
- Ozempic, Wegovy, Rybelsus, (semaglutide,) made by Novo Nordisk, is used for Type 2 diabetes, weight management, and cardiovascular health
- Trelegy Ellipta, made by GSK, is an inhaler used for chronic obstructive pulmonary disease and asthma
- Xtandi, made by Pfizer and Astellas Pharma, is used to treat prostate cancer in men
- Pomalyst, made by Bristol Myers Squibb, is used to treat a blood cancer called multiple myeloma and a cancer that develops in people with HIV
- Ibrance, made by Pfizer, is used to treat certain breast cancers
- Ofev, made by Boehringer Ingelheim, is used to treat chronic lung diseases in adults.
- Linzess, made by AbbVie and Ironwood Pharmaceuticals, is used to treat irritable bowel syndrome and chronic constipation
- Calquence, made by AstraZeneca, is used to treat certain types of blood cancer
- Austedo, Austedo XR, made by Teva Pharmaceuticals, is used to treat involuntary movements caused by tardive dyskinesia or Huntington’s disease
- Breo Ellipta, made by GSK and Theravance, is an inhaler used to treat chronic obstructive pulmonary disease
- Tradjenta, made by Boehringer Ingelheim and Eli Lilly, is used for Type 2 diabetes management
- Xifaxan, made by Salix Pharmaceuticals, is used to treat diarrhea caused by traveling or irritable bowel syndrome
- Vraylar, made by AbbVie, is used to treat schizophrenia, bipolar I disorder, and major depressive disorder
- Janumet, Janumet XR, made by Merck, is used to manage Type 2 diabetes
- Otezla, made by Amgen, is used to treat plaque psoriasis, psoriatic arthritis, and oral ulcers
President Joe Biden’s Inflation Reduction Act gave Medicare the power to directly hash out drug prices with manufacturers for the first time in the federal program’s nearly 60-year history. Some congressional Democrats and consumer advocates have long pushed for the…
Read More: Medicare drug price negotiations list includes Ozempic